Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management S.A. boosted its stake in Amneal Pharmaceuticals (NASDAQ:AMRX) by 75% in Q4, buying 1,611,698 shares to own 3,761,739 shares — about 1.20% of the company valued at roughly $47.4 million.
• Analysts are largely positive: the stock's average rating is a Buy with an average target of $14.20, and recent upgrades include Truist raising its target to $17 (Buy) and Zacks moving to Strong Buy.
• AMRX trades around $12.07 with a 12‑month range of $6.68–$15.42, a market cap near $3.8 billion and a trailing P/E of 52.48, reflecting a relatively high valuation versus historical levels.

Assenagon Asset Management S.A. boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 75.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,761,739 shares of the company's stock after purchasing an additional 1,611,698 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.20% of Amneal Pharmaceuticals worth $47,398,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company's stock worth $30,000 after purchasing an additional 1,957 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in Amneal Pharmaceuticals during the third quarter valued at approximately $31,000. Focus Partners Wealth bought a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $42,000. Advisory Services Network LLC acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, Bellevue Group AG bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $79,000. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Truist Financial raised their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Weiss Ratings reissued a "hold (c)" rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an "overweight" rating and a $15.00 price target for the company. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $14.20.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $12.07 on Wednesday. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.68 and a 12 month high of $15.42. The stock has a fifty day moving average price of $13.66 and a 200 day moving average price of $12.14. The company has a market cap of $3.80 billion, a P/E ratio of 52.48 and a beta of 1.35.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.